Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study

Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study

•Shingrix is poorly immunogenic following allogeneic hematopoietic cell transplantation independent of age, CD4, and B-cell recovery.•In hematopoietic cell transplantation recipients with antibody response to the vaccine, varicella zoster virus reactivation risk is not null.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood advances 2020-10, Vol.4 (19), p.4618-4622
Hauptverfasser: Camargo, Jose F., Lin, Rick Y., Natori, Yoichiro, Anderson, Anthony D., Alencar, Maritza C., Wang, Trent P., Morris, Michele I., Komanduri, Krishna V.
Format: Artikel
Sprache:eng
Schlagworte:
Hematopoietic Stem Cell Transplantation
Herpes Zoster
Herpes Zoster Vaccine
Humans
Pilot Projects
Stimulus Report
Vaccines, Synthetic
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Shingrix is poorly immunogenic following allogeneic hematopoietic cell transplantation independent of age, CD4, and B-cell recovery.•In hematopoietic cell transplantation recipients with antibody response to the vaccine, varicella zoster virus reactivation risk is not null.
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2020002269